Tumor mutation burden may become a biomarker for nivolumab in first line therapy for advanced NSCLC


Nivolumab is an immune checkpoint inhibitor for cancer treatment, and there are various ongoing clinical trials for nivolumab in different cancer types. The CheckMate 026 trial is a randomized trial comparing the treatment efficacy of nivolumab versus chemotherapy in first line therapy of advanced non-small cell lung cancer (NSCLC) based on the programmed death-ligand 1 (PD-L1) expression. However, there was no strong correlation between treatment response and PD-L1 expression. Therefore, researchers performed a subanalysis to assess if the tumor mutation burden (TMB) could determine nivolumab treatment response in 312 patients with evaluable TMB data. The results demonstrated that patients with a high mutation burden had a better progression free survival (9.7 vs 5.8 months; HR,0.62) and objective response rate (46.8% vs 28.3%) compared with the control arm. These findings imply that tumor mutation burden may be considered as a biomarker for nivoluamb in the first line treatment of advanced NSCLC.

 AACR annual meeting 2017: http://www.abstractsonline.com/pp8/#!/4292/presentation/12630

日韩av电影,色YEYE高清在线视频,欧美XXZOZO,JAPANESE 18日本护士